Free Trial
LON:AGY

Allergy Therapeutics 3/31/2025 Earnings Report

Allergy Therapeutics logo
GBX 8.18 +0.18 (+2.25%)
As of 06:53 AM Eastern

Allergy Therapeutics EPS Results

Actual EPS
-GBX 0.23
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Allergy Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Allergy Therapeutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Allergy Therapeutics Earnings Headlines

Allergy Therapeutics plc (AGY.L) - Yahoo Finance
Missed the Last 10,000% Surge? Here’s Your Next Chance
Axcelis Technologies went from $2.50 to $180—a staggering 7,100% return. These are the kinds of small-cap breakouts Fierce Analyst aims to catch before they go mainstream. Our research team uses data and trend analysis to uncover high-potential stocks early. And now, you can get free alerts on the next set of breakout candidates—before the crowd rushes in.tc pixel
Allergy Therapeutics Seeks Approval for Grass Allergy Treatment
Allergy Therapeutics Unveils Incentive Plans and Share Repurchase
See More Allergy Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Allergy Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Allergy Therapeutics and other key companies, straight to your email.

About Allergy Therapeutics

Allergy Therapeutics (LON:AGY) is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group has achieved over 9% compound annual growth since formation and employs c.500 employees.

View Allergy Therapeutics Profile

More Earnings Resources from MarketBeat